Browse key industry insights from the report “Lung Cancer Diagnostics Market Size,
Industry Analysis Report, Regional Outlook (U.S., Canada, Russia, Germany, China,
India, Brazil, South Africa), Application Development Potential, Price Trends,
Competitive Market Share & Forecast, 2017 – 2024” in detail along with the table of
contents:
https://www.gminsights.com/industry-analysis/lung-cancer-diagnostics-market
Based on the type, the industry can be segmented into small-cell and non-small cell lung
cancer. Non-small cell lung cancer (NSCLC) was identified as the largest segment, owing
to the availability of novel diagnostic testing, detecting the large tumor growths and is
also the most protuberant form in terms of occurrence, accounting for approximately 85
percent of the disease. Based on the test segment, the industry can be segmented into
imaging test, sputum cytology, biopsy and molecular testing. Imaging test segment was
identified as the largest test segment due to the high usage rates of several imaging
techniques including CT scan MRI and X-ray as the primary screening techniques used
for disease diagnosis
U.S. will witness significant growth over the forecast period due to the rising patient
awareness, high-pitched market penetration rates of technologically advanced products
and the escalated smoking prevalence level in the country. As per CDC statistics,
215,951 people in the U.S were diagnosed and approximately 155,526 people died from
the disease. Increased tobacco intake coupled with sedentary lifestyle will boost the
lung cancer diagnostics market size.
Asia Pacific will exhibit profitable growth over the forecast period. Increased prevalence
coupled with adoption of cutting-edge technologies will accelerate the revenue share.
India will grow at healthy rate due to presence of large patient pool requiring disease
screening. Increased health care expenditure coupled with rising awareness among
people witnesses to create lucrative growth opportunities.
Some of the industry players include Roche Diagnostics, Thermo Fisher Scientific,
Qiagen N.V., Agilent Technologies, AstraZeneca, Janssen and Sanofi S.A. Key strategies
adopted by the companies include strategic agreements, collaborations, geographical
expansion, mergers and acquisitions. Companies integrating technologies and methods
are the ones that will gain a competitive advantage and grow in today’s volatile business
environment.
2 | Page